Two CEOs are looking at noticeably different compensation packages this year when compared to last year.
Novartis CEO Vas Narasimhan, who recently took over as chair of the PhRMA board, last year brought home 8.4 million Swiss francs ($9 million), which was a 25% decrease from a year prior, when...
